Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Canada
18/07/2025 13:27
Amneal Pharmaceuticals Inc AMRX.O: KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG SUBMISSION FOR CREXONT® (CARBIDOPA AND LEVODOPA) EXTENDED-RELEASE CAPSULES IN CANADA Source text: ID:nGNX9DCgwV Further company coverage: AMRX.O
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil